103978-12-7

Basic information

• Product Name: Silane, [(3-bromophenyl)methoxy](1,1-dimethylethyl)dimethyl-
• CAS NO: 103978-12-7
• Molecular Formula: C13H21BrOSi
• Molecular Weight: 301.299
• Mol File: 103978-12-7.mol
• Article Data: 31

Chemical Properties

• CAS DataBase Reference: Silane, [(3-bromophenyl)methoxy](1,1-dimethylethyl)dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Silane, [(3-bromophenyl)methoxy](1,1-dimethylethyl)dimethyl-(103978-12-7)
• EPA Substance Registry System: Silane, [(3-bromophenyl)methoxy](1,1-dimethylethyl)dimethyl-(103978-12-7)

Safety Data

• Hazardous Substances Data: 103978-12-7(Hazardous Substances Data)

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 288-32-4 1H-imidazole 
• 15852-73-0 (3-Bromophenyl)methanol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 176640-03-2 1-(3-((tert-butyldimethylsilyloxy)methyl)phenyl)-2,2,2-trifluoroethanone 
• 410531-52-1 C₃₈H₅₂O₂Si₃ 
• 495402-49-8 2-[3-({[(tert-butyl)(dimethyl)silyl]oxy}methyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 178379-50-5 (1S,3aS,5S,7aR)-5-(3-methylphenyl)-3a-hydroxy-7a-methylperhydroindene-1-carboxaldehyde 
• 178379-51-6 (1S,3aS,5S,7aR)-1-hydroxymethyl-5-(3-methylphenyl)-7a-methylperhydroinden-3a-ol 
• 178379-35-6 (1S,3aS,5S,7aR)-3a-Hydroxy-5-(3-hydroxymethyl-phenyl)-7a-methyl-octahydro-indene-1-carbaldehyde 
• 392235-07-3 (1S,3aS,5S,7aR)-5-(3-tert-butyldimethylsilyloxymethylphenyl)-3a-hydroxy-7a-methylperhydroindene-1-carboxaldehyde 
• 410531-53-2 {3-[(3-hydroxymethyl-phenyl)-diphenyl-silanyl]-phenyl}-methanol 
• 410531-54-3 bis-(3-bromomethyl-phenyl)-diphenyl-silane 
• 410531-63-4 C₃₆H₃₅BrN₂OSi 
• 410531-61-2 C₄₂H₄₉BrN₂OSi₂ 
• 103978-30-9 ethyl 7-(3-t-butyldimethylsilyloxymethylphenyl)-1-ethyl-6-fluoro-1,4-dihydroquinol-4-one 3-carboxylate 

Relevant articles and documents

BENZODIAZEPINE DERIVATIVES

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formulae (I), (II) and (III). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

Structural Basis for Genetic-Code Expansion with Bulky Lysine Derivatives by an Engineered Pyrrolysyl-tRNA Synthetase

Yanagisawa et al. analyzed the Y306A/Y384F mutant of Methanosarcina mazei pyrrolysyl-tRNA synthetase (PylRS) with 17 non-natural, bulky oxycarbonyllysine derivatives for tRNAPyl aminoacylation and site-specific incorporation into proteins. Fourteen crystal structures of the amino acid-bound PylRS mutant revealed the structural bases of the binding. This information facilitates the structure-based design of novel amino acids. Pyrrolysyl-tRNA synthetase (PylRS) and tRNAPyl have been extensively used for genetic-code expansion. A Methanosarcina mazei PylRS mutant bearing the Y306A and Y384F mutations (PylRS(Y306A/Y384F)) encodes various bulky non-natural lysine derivatives by UAG. In this study, we examined how PylRS(Y306A/Y384F) recognizes many amino acids. Among 17 non-natural lysine derivatives, N?-(benzyloxycarbonyl)lysine (ZLys) and 10 ortho/meta/para-substituted ZLys derivatives were efficiently ligated to tRNAPyl and were incorporated into proteins by PylRS(Y306A/Y384F). We determined crystal structures of 14 non-natural lysine derivatives bound to the PylRS(Y306A/Y384F) catalytic fragment. The meta- and para-substituted ZLys derivatives are snugly accommodated in the productive mode. In contrast, ZLys and the unsubstituted or ortho-substituted ZLys derivatives exhibited an alternative binding mode in addition to the productive mode. PylRS(Y306A/Y384F) displayed a high aminoacylation rate for ZLys, indicating that the double-binding mode minimally affects aminoacylation. These precise substrate recognition mechanisms by PylRS(Y306A/Y384F) may facilitate the structure-based design of novel non-natural amino acids.

Design and synthesis of novel meta-linked phenylglycine macrocyclic FVIIa inhibitors

Two novel series of meta-linked phenylglycine-based macrocyclic FVIIa inhibitors have been designed to improve the rodent metabolic stability and PK observed with the precursor para-linked phenylglycine macrocycles. Through iterative structure-based design and optimization, the TF/ FVIIa Ki was improved to subnanomolar levels with good clotting activity, metabolic stability, and permeability.